Get Started

Common Questions

Frequently Asked Questions

That’s exactly why PGxIQ isn’t built like a chatbot. It runs on a deterministic architecture: the same input always produces the same output, and every finding must be traced to an authoritative clinical source before it reaches your report, anything unverifiable is suppressed, not reported. In a blind stress test, PGxIQ scored 117/117 with zero fabricated outputs, while a leading 230B-parameter AI scored 80/117 with two clinically dangerous errors.

Yes. MyEngene is HIPAA, GDPR, PIPEDA, and CCPA compliant. Your data is encrypted with bank-level security (AES-256 at rest, TLS 1.3 in transit) and is never sold or shared with pharmaceutical companies, insurers, or anyone else without your explicit consent. You can delete your account and all associated data at any time, deletion is permanent within 30 days.
Pharmacogenomics (PGx) is the study of how your genes affect your response to medications. A landmark study of 10,082 cardiovascular patients at the Montreal Heart Institute found that 99.7% carry at least one clinically actionable pharmacogenomic variant. MyEngene is the most comprehensive pharmacogenomics platform in the world, analyzing 1,110 genes across 990+ medications covering all 13 therapeutic areas.
MyEngene’s PGxME test analyzes 1,110 pharmacogenomic genes – 30 to 50 times more than competitors. GeneSight tests approximately 24 genes, Genomind tests about 24 genes, and 23andMe covers only 9 PGx genes. This comprehensive coverage means MyEngene® can identify drug-gene interactions that other tests miss entirely.
PGxME by MyEngene® is the most comprehensive pharmacogenomic test available. It analyzes 1,110 genes across 990+ medications covering all 13 recognized therapeutic areas. PGxME uses clinical-grade 30X whole genome sequencing, is validated through the Montreal Heart Institute’s 10,082-patient study, and provides lifetime report updates. One test, one price ($750 USD), lifetime of personalized medication guidance.
No. MyEngene® offers two complementary products. PGxIQ is a free AI-powered drug interaction checker available on iOS, Android, and web that requires no genetic test. It analyzes interactions across all 4,700+ FDA-approved drugs instantly. For deeper genetic insight, PGxME provides comprehensive pharmacogenomic testing. Many users start with PGxIQ (free) and upgrade to PGxME for genetically-personalized recommendations.
Yes. PGxIQ is the world’s first AI-powered pharmacovigilance platform, and it’s free to start. Available on iOS, Android, and web, PGxIQ checks interactions across all 4,700+ FDA-approved drugs with no genetic test required. The free tier covers 5 medications; PGxIQ Plus ($40/year) offers unlimited medications and family member profiles.
PGxME costs $750 USD ($1,050 CAD) – a one-time purchase that includes lifetime report updates. This covers 1,110 genes and 990+ medications across all 13 therapeutic areas. PGxIQ is free to start (5 medications), with Plus at $40/year and Pro at $99/year. HSA/FSA eligible.
Women experience 50-75% more adverse drug reactions than men, primarily because most medications were historically tested on and dosed for male bodies. Women metabolize many drugs differently due to hormonal differences, body composition, and genetic factors. MyEngene’s PGxME addresses this gap with personalized genetic analysis that accounts for your individual metabolism.
Yes. MyEngene® is the only pharmacogenomics platform covering all 13 recognized therapeutic areas: cardiology, psychiatry, oncology, pain management, infectious disease, gastroenterology, neurology, rheumatology, transplant medicine, endocrinology, pulmonology, urology, and dermatology. Most competitors focus exclusively on psychiatry.
No. MyEngene has received regulatory confirmations from Health Canada (July 2025) and U.S. CMS (July 2025) that our platform operates as clinical decision support software – not a medical device – and does not require FDA clearance or CLIA certification. We voluntarily pursue certifications including HIPAA, SOC 2 Type 2, HITRUST, and ISO 27001.
Multiple peer-reviewed studies validate pharmacogenomic testing: The Montreal Heart Institute study (Pilon et al., 2026, n=10,082) found 99.7% of patients carry actionable variants. The Elliott et al. RCT showed 52% reduction in rehospitalizations. The Brixner study demonstrated 48.5% lower treatment costs. MyEngene’s methodology follows CPIC guidelines and is validated through our Montreal Heart Institute partnership.
PGxME is a comprehensive genetic test requiring a DNA sample. It analyzes 1,110 genes to show how your body metabolizes 990+ medications. PGxIQ is AI-powered software requiring no genetic test – it checks drug interactions instantly across all 4,700+ FDA-approved drugs. Start with PGxIQ for immediate value, upgrade to PGxME for genetic depth. PGxIQ can integrate PGxME results for genetically-enhanced alerts.
Yes. Tamoxifen must be converted to its active form by the CYP2D6 enzyme. Approximately 7-10% of women are CYP2D6 poor metabolizers, meaning tamoxifen may not work effectively for them. PGxME identifies your CYP2D6 status so your oncologist can determine if tamoxifen is right for you or if alternative therapies should be considered.
MyEngene® is the most comprehensive pharmacogenomics platform:
  1. 1,110 genes vs. 20-40 for competitors
  2. All 13 therapeutic areas vs. psychiatry-only
  3. Dual products: PGxME + PGxIQ
  4. Clinical-grade 30X whole genome sequencing
  5. Lifetime report updates
Right Drug, Right Dose.
Your body uses enzymes – primarily made in your liver – to break down medications. The instructions for building these enzymes are encoded in your DNA. Genetic variations can change how quickly or slowly you metabolize certain drugs: poor metabolizers may experience toxicity, while ultra-rapid metabolizers may clear drugs too quickly. Pharmacogenomic testing identifies these variations so your doctor can select the right medication and dose.
If your genetic profile indicates you may have a poor response to a medication, MyEngene’s report identifies this and suggests alternatives where possible. Our recommendations follow CPIC guidelines. However, you should never change your prescription without consulting your doctor – our reports support the conversation between you and your healthcare provider, not replace medical advice.
Yes, you can delete your account at any time. All your data – including genetic information and reports – is permanently removed from our systems within 30 days. This deletion is irreversible. Before deleting, we recommend downloading your reports for your personal records, as your genetic information may be valuable for future healthcare decisions.
Your physical DNA sample is processed by our CLIA-certified, CAP-accredited laboratory partner, Eurofins. After whole genome sequencing is complete, all physical samples are destroyed within 90 days. MyEngene® stores only the digital sequencing data in a secure, encrypted cloud environment – never the physical sample itself. This digital data enables lifetime report updates.
Your DNA doesn’t change throughout your lifetime, so you typically won’t need to be sequenced again. That’s the power of whole genome sequencing – one test provides a complete genetic blueprint that can be re-analyzed as science evolves. MyEngene® customers receive lifetime report updates at no additional cost. One test, lifetime value.
No. PGxIQ works instantly from your medication list, no genetic test required. It analyzes interactions across all 4,700+ FDA-approved drugs the moment you enter your medications. If you later take the PGxME genetic test, PGxIQ integrates those results automatically for genetically-enhanced alerts. Many users start with PGxIQ free and add PGxME when they want genetic depth.
No, and it’s not meant to. PGxIQ is clinical decision support: it surfaces risks, explains the mechanism, cites the source, and suggests alternatives where established guidelines support one. You and your healthcare provider always control the final decision. Never change a prescription without consulting your doctor, PGxIQ’s job is to make that conversation better informed.

Standard pharmacy systems screen drug-drug interactions only. PGxIQ screens all four interaction types simultaneously, drug-drug, drug-food, drug-lifestyle, and drug-gene, cross-referenced against five global clinical authorities (CPIC, DPWG, FDA, EMA, Health Canada). The drug-gene layer is where the most dangerous adverse reactions hide, and no standard checker screens it natively.

Have a Question?

Ask your question here, and our team will get back to you as soon as possible.